Skip to main content
Clinical Trials/CTRI/2024/03/063481
CTRI/2024/03/063481
Not yet recruiting
Phase 3

Efficacy and Safety of Anticoagulation in patients with Digital Gangrene and an underlying Connective Tissue Disease - NI

Department of Clinical Immunology & Rheumatology0 sites0 target enrollmentTBD

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Health Condition 1: M339- Dermatopolymyositis, unspecifiedHealth Condition 2: M319- Necrotizing vasculopathy, unspecifiedHealth Condition 3: M340- Progressive systemic sclerosisHealth Condition 4: M368- Systemic disorders of connective tissue in other diseases classified elsewhereHealth Condition 5: M359- Systemic involvement of connectivetissue, unspecifiedHealth Condition 6: M321- Systemic lupus erythematosus withorgan or system involvement
Sponsor
Department of Clinical Immunology & Rheumatology
Status
Not yet recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional

Investigators

Sponsor
Department of Clinical Immunology & Rheumatology

Eligibility Criteria

Inclusion Criteria

  • 1\. Patients with digital gangrene of duration less than or equal to 1 month, defined as bluish blackish
  • discoloration of any digit, including pre\-gangrenous changes in the form of intense pain, pallor
  • and/or dusky colour change of digits and delayed capillary refill time.
  • 2\. Patients with a diagnosis of Connective tissue disorder (CTD) as per latest standard
  • diagnostic/classification criteria

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Not specified

Similar Trials